Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04761783 · ClinicalTrials.gov registry record
BESPOKE Study of ctDNA Guided Immunotherapy
A clinical trial, sponsored by Natera.
- Completed
- Registry status
- 290
- Enrollment target
NCT04761783 is a clinical trial that has completed, run by Natera. The registered enrollment target is 290 participants.
The verdict
NCT04761783 has completed, sponsored by Natera.
- COMPLETED
- Registry status
- 290 participants
- Enrollment target
Study Summary
This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tumor response. The correlation between SIGNATERA™ test results and subsequent treatment decisions will be examined to compare actual treatment delivered against treatment decisions potentially impacted by SIGNATERA™ results. Treatment administered, tumor assessment results, time to progression, overall survival, physician questionnaires, and patient-reported outcomes will be collected/recorded.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2024-03-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04761783
The ClinicalTrials.gov registry entry for NCT04761783 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04761783 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04761783 about?
NCT04761783 is a clinical study titled "BESPOKE Study of ctDNA Guided Immunotherapy". This is a prospective data collection study of patients with advanced solid tumors who will receive standard of care immunotherapy (IO) and will be monitored with SIGNATERA™ testing. SIGNATERA™ test will be performed at baseline and during routine care. The test results will be part of assessing tum...
What is the current status of trial NCT04761783?
This trial is currently completed. The enrollment target is 290 participants. The study started on 2021-05-28. Estimated completion is 2024-03-30.
Who is sponsoring clinical trial NCT04761783?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.